Rep. Lisa C. McClain (R-MI) Buys ImmunityBio (IBRX) Stock
Rep. Lisa C. McClain made a stock purchase in ImmunityBio, Inc., valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Lisa C. McClain (R-MI) bought between $1,001 and $15,000 of ImmunityBio, Inc. ($IBRX) stock on September 28, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed October 12, 2026.
Since the trade, $IBRX is up 21.8% after 1 week and up 7.8% to date (from the $8.52 close on Sep 28, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Lisa C. McClain (R)
- Status:
- Member — House
- Party:
- Republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Oct 12, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| ImmunityBio, Inc. ($IBRX) | Buy | Sep 28, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. View the original: STOCK Act disclosure (House Clerk)
IBRX
ImmunityBio, Inc.
Key Points
- On September 28, 2026, Rep. Lisa C. McClain bought shares of ImmunityBio, Inc. (IBRX) valued between $1,001 and $15,000.
- The stock recently traded around $9.30, which is above its 50-day moving average of $8.47 and 200-day average of $7.52.
- ImmunityBio has a market cap of about $10.6 billion and is focused on developing immunotherapies for cancer and infectious diseases.
Get $IBRX trade alerts by text
We text you when insiders, Congress or big funds trade $IBRX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ImmunityBio, Inc. alert may contain errors. Disclosures
Rep. Lisa C. McClain purchased shares of ImmunityBio, Inc. (IBRX) valued between $1,001 and $15,000 on September 28, 2026. This trade was disclosed in a periodic transaction report filed under the STOCK Act on October 12, 2026. McClain is a Republican member of the House representing Michigan's 9th district.
Lisa C. McClain vs. the S&P 500
Hypothetical returns from Lisa C. McClain's disclosed trades, not real profit or advice. How we model this.
What Changed in Lisa C. McClain's ImmunityBio Position
McClain's recent transaction adds to her investment profile as she continues to engage in stock purchases.
Other Institutional Activity in ImmunityBio
Several institutional investors are also involved with ImmunityBio. Blackrock Inc. holds 34,083,262 shares worth about $312.9 million, having increased its position by 7,737,693 shares. State Street Corporation owns 21,398,438 shares valued at around $196.4 million, growing its stake by 3,690,363 shares. Vanguard Portfolio Management LLC has 17,863,911 shares worth approximately $164 million, with an increase of 1,540,893 shares.
ImmunityBio, Inc. Stock Down 7.2%
As of October 16, 2026, ImmunityBio's stock was recently trading around $9.30. This price is above its 50-day moving average of $8.47 and its 200-day average of $7.52. However, it remains about 25.2% below its 52-week high of $12.43.
Recent Earnings
ImmunityBio reported trailing twelve-month revenue of $165.8 million. The company has not yet turned a profit, with an EPS of -0.97. The next earnings report is expected on November 3, 2026.
Insider Buying and Selling at ImmunityBio, Inc.
Several insiders have sold shares recently. Barry Simon sold 25,000 shares on June 24, 2026, at an average price of $7.88, totaling $197,000. Christobel E. Selecky, a director, sold 159,478 shares at $9.02, valued at $1.4 million, on July 1, 2026. Additionally, Cheryl L. Cohen, also a director, sold 131,210 shares at $9.50, totaling approximately $1.2 million on July 2, 2026.
Analysts Set New Price Targets
On October 15, 2026, Jefferies maintained its "Buy" rating and raised the price target for ImmunityBio to $14.00, up from $12.00. HC Wainwright & Co. also reiterated a "Buy" rating with a target of $15.00, indicating strong confidence in the stock's potential. The consensus from analysts suggests a strong buy recommendation with a mean price target of $14.25.
About ImmunityBio, Inc.
ImmunityBio, Inc. is a biotechnology company based in San Diego, CA. It focuses on developing next-generation immunotherapies aimed at activating the immune system to combat cancer and infectious diseases. With a workforce of 684 employees, the company is pushing forward in the healthcare sector, seeking innovative solutions for serious health challenges.
Bottom Line
Investors should keep an eye on ImmunityBio's upcoming earnings report on November 3, 2026, and any further disclosures from Rep. McClain regarding her stock trades. This recent purchase adds to her active trading history in the market.
Related Filing Alerts
Source: Lisa C. McClain's STOCK Act disclosure on $IBRX (Sep 28, 2026). Read the original filing: STOCK Act disclosure (House Clerk). Written by software, not financial advice. How we make alerts